Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 4.9 (52)
  • Medicine

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

    2d ago ·  Video

    RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

    Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively. Topics Covered: Overview of the RASolute-302 study Impact of Daraxonrasib on overall survival RAS mutations in pancreatic cancer Mechanism of action of RAS inhibitors Side effects and management strategies Tune in now for an enlightening discussion on the future of pancreatic cancer treatment! #ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

    27 min
  2. ESMO Breast 2026 Highlights - VERITAC-2, PREcoopERA, PHERGain, SATEEN/BRE-354, TROPION-Breast02

    May 26 ·  Video

    ESMO Breast 2026 Highlights - VERITAC-2, PREcoopERA, PHERGain, SATEEN/BRE-354, TROPION-Breast02

    Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into key studies and recent FDA approvals, including: The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer. The importance of ovarian function suppression in premenopausal patients, even with the advent of oral SERDs. Updates on HER2-positive disease treatments, including the newly approved T-DXd in neoadjuvant settings and the implications of de-escalation strategies. Insights from the SATEEN and BRE-354 studies on the use of antibody-drug conjugates (ADCs) after previous ADC treatments. A look at the Dato-DXd and Sacituzumab in frontline triple-negative breast cancer and how to choose between them. Join us as we unpack these critical findings and their implications for clinical practice. Don't forget to check out our other episodes for more treatment algorithms and conference highlights. Stay tuned for ASCO 2026, and remember, we are the Oncology Brothers! #ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers

    22 min
  3. Challenging Cases in Relapsed/Refractory Acute Myeloid Leukemia (AML): Dr. Joshua Zeidner

    May 25 ·  Video

    Challenging Cases in Relapsed/Refractory Acute Myeloid Leukemia (AML): Dr. Joshua Zeidner

    In this episode of the Oncology Brothers podcast, we dived deep into the complexities of relapsed refractory acute myeloid leukemia (AML) with expert guest Dr. Joshua Zeidner, Chief of Leukemia Research at the University of North Carolina. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore two challenging cases: Revumenib (menin inhibitor) demonstrated an overall response rate of ~63% in heavily pre-treated KMT2A rearrangement-positive AML patients based on the AUGMENT-101 study, with QTc prolongation and CYP3A4 drug interactions as key monitoring considerations. FLT3 inhibitors like gilteritinib and quizartinib play an important role in MRD-positive FLT3 ITD/NPM1-mutated AML post-transplant, with the MORPHO trial supporting gilteritinib as maintenance therapy.  Menin inhibitors may have a broader role in high-risk AML including NPM1-mutated disease, and re-evaluating mutational profiles at relapse is critical for optimal treatment selection.  Careful monitoring of side effect profiles, drug interactions, and MRD status is essential when navigating targeted therapy decisions in relapsed refractory AML. Throughout the episode, we discuss key practical points, including the importance of monitoring for QTc prolongation and the impact of drug interactions with CYP3A4 inhibitors. Tune in for an informative discussion that sheds light on the latest advancements in targeted therapies for AML and the evolving landscape of treatment options. Don't forget to like, subscribe, and check out our other episodes in the challenging case series, treatment algorithms, and conference highlights! #AcuteMyeloidLeukemia, #MeninInhibitor, #FLT3Inhibitor, #Hematology, #OncologyBrothers

    25 min
  4. Challenging Cases in Chronic Myeloid Leukemia (CML): Drs. Fadi Haddad & Gaby Hobbs

    May 22 ·  Video

    Challenging Cases in Chronic Myeloid Leukemia (CML): Drs. Fadi Haddad & Gaby Hobbs

    Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of chronic myeloid leukemia (CML) through two challenging case studies. Joined by CML experts Dr. Fadi Haddad from MD Anderson Cancer Center and Dr. Gaby Hobbs from Massachusetts General Hospital,  Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ we talked about: The initial workup for diagnosing CML, including the importance of CBC, bone marrow biopsy, and BCR-ABL testing. How to select the most optimal frontline treatment option amongst many available, considering factors like age, comorbidities, and the goal of treatment-free remission (TFR). The role of first-generation TKI, but also how newer TKIs assist in achieving deeper molecular remissions. Strategies for managing treatment breaks and monitoring patients in remission. The role of ponatinib as a pan-BCR:ABL1 inhibitor effective against all known resistance mutations, including T315I, and the optimized response-based dosing strategy to balance efficacy with safety. Tune in for valuable insights on treatment strategies, patient management, and the latest advancements in CML care. Don't forget to like, subscribe, and share your challenging case scenarios for future discussions! #ChronicMyeloidLeukemia, #CML, #TreatmentFreeRemission, #OncologyBrothers

    22 min
  5. Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson

    May 20 ·  Video

    Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson

    In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of the efficacy and survival data for both combinations Side effect profiles and management strategies Clinical pearls for oncologists in practice The importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapy Join us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life. Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights! #BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers

    22 min
  6. Treating BRAF V600E Mutated Non-Small Cell Lung Cancer (NSCLC) with Dr. Gregory Riely

    May 18 ·  Video

    Treating BRAF V600E Mutated Non-Small Cell Lung Cancer (NSCLC) with Dr. Gregory Riely

    Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of BRAF V600E-driven non-small cell lung cancer (NSCLC) with our guest Dr. Gregory Riely, a thoracic medical oncologist from Memorial Sloan Kettering Cancer Center. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore: The prevalence of BRAF V600E mutations in NSCLC and how they compare to other oncogenic drivers. The latest treatment options, including BRAF-MEK inhibitors like Encorafenib-Binimetinib and Dabrafenib-Trametinib. Key clinical trial data that led to the approval of these therapies and their implications for patient care. The role of immunotherapy in treating BRAF V600E patients and how to effectively sequence treatments. Patient characteristics that influence treatment decisions, including smoking history and PD-L1 expression. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't miss it! Subscribe to our channel for more discussions on oncology and stay updated on the latest in cancer care! #BRAFV600E, #NSCLC, #BRAFMEKinhibitor, #TargetedTherapy, #OncologyBrothers

    19 min
  7. Managing Toxicities of Bispecific Antibodies in Multiple Myeloma–Drs. Hamza Hashmi & Cesar Rodriguez

    May 15 ·  Video

    Managing Toxicities of Bispecific Antibodies in Multiple Myeloma–Drs. Hamza Hashmi & Cesar Rodriguez

    Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of bispecific antibodies, focusing on GPRC5D and BCMA-targeted therapies. Detailed discussion on talquetamab, teclistamab, elranatamab, and linvoseltamab, including dosing, side effects, and management strategies. Insights on managing cytokine release syndrome (CRS), neurotoxicity, and other side effects like dysgeusia, skin toxicity, and infections. Prophylactic measures, including the use of IVIG and tocilizumab, to enhance patient care and quality of life. Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers

    28 min
  8. Managing Toxicities of EGFR Inhibitors in Lung Cancer – Drs. Azam Farooqui & Joshua Sabari

    May 13 ·  Video

    Managing Toxicities of EGFR Inhibitors in Lung Cancer – Drs. Azam Farooqui & Joshua Sabari

    In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics include: The role of afatinib in treating uncommon EGFR mutations and its associated toxicities The well-tolerated profile of osimertinib and its common side effects, including rash, diarrhea, and the rare risk of pneumonitis Insights into the combination therapy of amivantamab and lazertinib, including management of skin toxicity and the importance of prophylactic anticoagulation to mitigate VTE risks The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting. Don’t forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights! #LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers

    23 min
See All (100)

4.9
out of 5
52 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like